A.O.U. Maggiore della Carità
A.O.U. Maggiore della Carità
Novara, Italy4 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Non-interventional Study of Participants With BPDCN Treated With Chemotherapy | CD4+/CD56+ hematodermic neoplasm, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Skin and Connective Tissue Diseases, hematologic disorder, hematopoietic and lymphoid system neoplasm, leukemia, lymphoma, malignant histiocytosis, neoplasm, skin disorder, skin neoplasm | Recruiting | Not stated | 2026-09-15 | NCT07785180 | |
| Validating DW-MRI and Fat Fraction in Multiple Myeloma Post-ASCT: The RAC-FAT Study" | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Not yet recruiting | Not stated | 2026-09-09 | NCT07746232 | |
| European Myeloma Network (EMN) Sample Project | Blood Protein Disorders, Hemic and Lymphatic Diseases, Hypergammaglobulinemia, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, leukemia, lymphoproliferative syndrome, monoclonal gammopathy, monoclonal gammopathy of uncertain significance, neoplasm, plasma cell leukemia, plasma cell neoplasm, precancerous condition, smoldering plasma cell myeloma, vascular disorder, vascular hemostatic disease | Recruiting | Not stated | 2025-12-03 | NCT06237803 | |
| Efficacy and Safety of Luspatercept for the Treatment of Anemia Due to MDS With del5q, Refractory/Resistant/Intolerant to Prior Treatments, RBC-TD | Hemic and Lymphatic Diseases, anemia, bone marrow disorder, hematologic disorder, myelodysplastic syndrome | Recruiting | Phase 2 | 2024-11-18 | NCT05924100 |